Minnesota

Psychedelic trials in Minnesota

27 registered trials has a study site in Minnesota, and 4 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654 · COMPASS Pathways	Recruiting	Phase 2 / Phase 3	psilocybin	8
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	79
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	44
Intravenous Ketamine for Treatment-Resistant DepressionNCT06668571 · Mayo Clinic	Recruiting	Phase 2	ketamine	1

Facilities

Where the research happens in Minnesota

Facility	City	Trials
Mayo Clinic in Rochester	Rochester	4
Minneapolis VA Health Care System, Minneapolis, MN	Minneapolis	4
Mayo Clinic	Rochester	3
University of Minnesota	Minneapolis	3
Institute for Integrative Therapies	Eden Prairie	2
Minneapolis VA Medical Center	Minneapolis	2
MN	Eden Prairie	1
The Remedy Mental Health	Golden Valley	1
St. Mary's Duluth Clinic Health System	Duluth	1
M Health Fairview DBT Program	Minneapolis	1
M Physicians St. Louis Park Clinic	Saint Louis Park	1
Minneapolis Veterans Affairs Health Care System	Minneapolis	1
Minneapolis Va Health Care System, Minneapolis MN	Minneapolis	1
Hennepin County Medical Center	Minneapolis	1

Stay told

When a trial opens in Minnesota

All trials

Every trial with a Minnesota site

Trial	Status	Phase	Substance	Sites
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654 · COMPASS Pathways	Recruiting	Phase 2 / Phase 3	psilocybin	8
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	79
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	44
Intravenous Ketamine for Treatment-Resistant DepressionNCT06668571 · Mayo Clinic	Recruiting	Phase 2	ketamine	1
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.NCT03156504 · Mayo Clinic	Completed	Phase 4	ketamine	4
Ketamine Frequency Treatment for Major Depressive DisorderNCT00646087 · Essentia Health	Withdrawn	Phase 4	ketamine	1
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
Ketamine-enhanced Prolonged Exposure Therapy in PTSDNCT04560660 · VA Office of Research and Development	Completed	Phase 2	ketamine	1
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	14
Efficacy of Repeated Ketamine Infusions for Treatment-resistant DepressionNCT02360280 · VA Office of Research and Development	Completed	Phase 2	ketamine	1
Ketamine Treatment for PTSD and MDD in TBINCT06228391 · Minneapolis Veterans Affairs Medical Center	Not yet recruiting	Phase 2	ketamine	1
CAP-Ketamine for Antidepressant Resistant PTSDNCT02655692 · VA Office of Research and Development	Completed	Phase 2	ketamine	3
Ketamine and Prolonged Exposure in PTSDNCT03960658 · Minneapolis Veterans Affairs Medical Center	Completed	Phase 1 / Phase 2	ketamine	1
Ketamine in Adolescents With Treatment-Resistant DepressionNCT02078817 · University of Minnesota	Completed	Phase 2	ketamine	1
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving KetamineNCT03290963 · William V. Bobo, M.D.	Withdrawn	Phase 2	ketamine	1
Ketamine for Depression and Suicide RiskNCT02094898 · Mayo Clinic	Completed	Phase 2	ketamine	1
ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality DisorderNCT07833761 · University of Minnesota	Not yet recruiting	Phase 1	psilocybin	2
Repeated Ketamine Infusions for Comorbid PTSD and MDD in VeteransNCT04032301 · University of Minnesota	Completed	Phase 1	ketamine	1
Visual Surround Suppression and Perceptual Expectation Under PsilocybinNCT04424225 · University of Minnesota	Terminated	Phase 1	psilocybin	1
Ketamine Infusions for PTSD and Treatment-Resistant DepressionNCT02577250 · Minneapolis Veterans Affairs Medical Center	Completed	Phase 1	ketamine	1
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:NCT03573349 · Mayo Clinic	Active, not recruiting	Early Phase 1	ketamine	1
Effect of Ketamine and Etomidate During RSI on Long Term OutcomesNCT06179485 · Vanderbilt University Medical Center	Enrolling by invitation	N/A	ketamine	6
Ketamine Anesthesia in Electroconvulsive TherapyNCT01367119 · Mayo Clinic	Completed	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-10-06.

Elsewhere